Hilary Baldwin1, Daisy Blanco2, Charles McKeever3, Nelly Paz4, Ynca Nina Vasquez5, John Quiring6, Carolyn Enloe7, Emily De León7, Nathan Stasko7. 1. Acne Research and Treatment Center, Morristown, New Jersey; 2. Instituto Dermatológico y Cirugía de Piel, Santo Domingo, Dominican Republic; 3. Hospital Punta Pacifica, Panama City, Panama; 4. Hospital y Clínica Bendaña, San Pedro Sula, Honduras; 5. Instituto Dermatológico y Cirugía de Piel, San Cristobal, Dominican Republic; 6. QST Consultations, Allendale, Michigan; 7. Novan, inc, Durham, North Carolina.
Abstract
OBJECTIVE: To compare efficacy, tolerability, and safety of two concentrations of topical SB204 and vehicle twice daily for 12 weeks in the treatment of acne vulgaris. DESIGN: Randomized, double-blind, placebo-controlled, three-arm, Phase 2 study. SETTING: Dominican Republic, Panama, and Honduras. PARTICIPANTS: Subjects with acne, age 12 to 40, with 25 to 70 noninflammatory lesions, 20 to 40 inflammatory lesions, and a baseline Investigator's Global Assessment score of mild, moderate, or severe. MEASUREMENTS: The primary efficacy assessment was the absolute change in noninflammatory lesion counts. Other assessments included inflammatory lesion counts, success on dichotomized Investigator's Global Assessment, reported adverse events, physical examinations, laboratory testing, and tolerability. RESULTS:One hundred fifty-three subjects were randomized to vehicle (n=52), SB204 1% (n=51), or SB204 4% (n=50). When compared to vehicle, subjects treated with SB204 1% and SB204 4% had significantly greater mean percent reduction in noninflammatory lesions from baseline and subjects treated with SB204 4% had a significantly greater mean percent reduction in inflammatory lesion count from baseline at Week 12. There were no significant differences in the IGA success rates between groups. Both concentrations of SB204 were safe and well-tolerated. CONCLUSIONS: When compared to vehicle, both SB204 1% and SB204 4% significantly decreased the percentage of noninflammatory lesions and SB204 4% also significantly decreased the percentage of inflammatory lesions in subjects with acne vulgaris treated for 12 weeks. Treatment with SB204 1% and SB204 4% was safe and well-tolerated. Registry: clinicaltrials.gov (NCT01844752).
RCT Entities:
OBJECTIVE: To compare efficacy, tolerability, and safety of two concentrations of topical SB204 and vehicle twice daily for 12 weeks in the treatment of acne vulgaris. DESIGN: Randomized, double-blind, placebo-controlled, three-arm, Phase 2 study. SETTING: Dominican Republic, Panama, and Honduras. PARTICIPANTS: Subjects with acne, age 12 to 40, with 25 to 70 noninflammatory lesions, 20 to 40 inflammatory lesions, and a baseline Investigator's Global Assessment score of mild, moderate, or severe. MEASUREMENTS: The primary efficacy assessment was the absolute change in noninflammatory lesion counts. Other assessments included inflammatory lesion counts, success on dichotomized Investigator's Global Assessment, reported adverse events, physical examinations, laboratory testing, and tolerability. RESULTS: One hundred fifty-three subjects were randomized to vehicle (n=52), SB204 1% (n=51), or SB204 4% (n=50). When compared to vehicle, subjects treated with SB204 1% and SB204 4% had significantly greater mean percent reduction in noninflammatory lesions from baseline and subjects treated with SB204 4% had a significantly greater mean percent reduction in inflammatory lesion count from baseline at Week 12. There were no significant differences in the IGA success rates between groups. Both concentrations of SB204 were safe and well-tolerated. CONCLUSIONS: When compared to vehicle, both SB204 1% and SB204 4% significantly decreased the percentage of noninflammatory lesions and SB204 4% also significantly decreased the percentage of inflammatory lesions in subjects with acne vulgaris treated for 12 weeks. Treatment with SB204 1% and SB204 4% was safe and well-tolerated. Registry: clinicaltrials.gov (NCT01844752).
Authors: David A Wink; Harry B Hines; Robert Y S Cheng; Christopher H Switzer; Wilmarie Flores-Santana; Michael P Vitek; Lisa A Ridnour; Carol A Colton Journal: J Leukoc Biol Date: 2011-01-13 Impact factor: 4.962
Authors: Bibhuti B Mishra; Vijay A K Rathinam; Gregory W Martens; Amanda J Martinot; Hardy Kornfeld; Katherine A Fitzgerald; Christopher M Sassetti Journal: Nat Immunol Date: 2012-11-18 Impact factor: 25.606
Authors: Benjamin J Privett; Angela D Broadnax; Susanne J Bauman; Daniel A Riccio; Mark H Schoenfisch Journal: Nitric Oxide Date: 2012-02-18 Impact factor: 4.427
Authors: Jenny Kim; Maria-Teresa Ochoa; Stephan R Krutzik; Osamu Takeuchi; Satoshi Uematsu; Annaliza J Legaspi; Hans D Brightbill; Diana Holland; William J Cunliffe; Shizuo Akira; Peter A Sieling; Paul J Godowski; Robert L Modlin Journal: J Immunol Date: 2002-08-01 Impact factor: 5.422
Authors: Evan M Hetrick; Jae Ho Shin; Nathan A Stasko; C Bryce Johnson; Daniel A Wespe; Ekhson Holmuhamedov; Mark H Schoenfisch Journal: ACS Nano Date: 2008-02 Impact factor: 15.881
Authors: Min Qin; Angelo Landriscina; Jamie M Rosen; Gabrielle Wei; Stephanie Kao; William Olcott; George W Agak; Karin B Paz; Josephine Bonventre; Alicea Clendaniel; Stacey Harper; Brandon L Adler; Aimee E Krausz; Joel M Friedman; Joshua D Nosanchuk; Jenny Kim; Adam J Friedman Journal: J Invest Dermatol Date: 2015-07-14 Impact factor: 8.551
Authors: Min Qin; Aslan Pirouz; Myung-Hwa Kim; Stephan R Krutzik; Hermes J Garbán; Jenny Kim Journal: J Invest Dermatol Date: 2013-07-24 Impact factor: 8.551